Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - WuXi PharmaTech CEO Ge Li showed his disappointment about the terminated merger with Charles River Laboratories, stressed the near-term impact will be minor, and promised to continue development of WuXi's toxicology services, during an Aug. 2 earnings call

You may also be interested in...



Charles River Abandons WuXi PharmaTech Just Days Before Crucial Shareholder Votes On Planned Merger

BEIJING - Like a prospective bride who has been jilted at the very last moment by a suitor, Shanghai's WuXi PharmaTech has been abandoned by the Massachusetts-headquartered Charles River Laboratories on the eve of the two contract research organizations' merger

China Anticipates Speeding Up R&D By Joining OECD As Observer - DIA China Conference

BEIJING - China's status as an observer country in the Organization for Economic Cooperation and Development will help the local contract research organization sector get faster access to the world's top biomedical markets for drugs developed and tested in China, said leaders at DIA's China conference May 19

China's Wuxi PharmaTech Signs New Agreement On Toxicology Studies Training And Services With J&J Unit

BEIJING - Just days after disclosing that a newly launched drug safety testing center had been accredited by a U.S. group, leading Chinese contract research organization Wuxi PharmaTech signed a toxicology deal with Johnson & Johnson Pharmaceutical Research & Development

Related Content

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel